Akari Therapeutics Financial Results
Akari Therapeutics reported third quarter 2026 financial results and highlighted the initiation of GLP toxicology studies for its lead TROP2-targeted ADC candidate, AKTX-101. The company ended the quarter with $5.7 million in cash and is progressing toward a planned Phase 1 clinical trial in mid-2027, subject to additional financing.
- Term
- Q3 2026
“We are entering an increasingly important phase in Akari’s evolution, as we translate the differentiated potential of our PH1 payload platform into a defined path toward clinical development. The initiation of GLP toxicology studies represents a critical step toward bringing AKTX-101 into the clinic.”
Abizer Gaslightwala, President and Chief Executive Officer
“The ADC landscape is rapidly evolving, and we believe the next wave of innovation will be driven not simply by new targets, but by novel payloads capable of overcoming the limitations of current treatments. That is precisely the opportunity we are pursuing with the PH1 payload.”
Abizer Gaslightwala, President and Chief Executive Officer